中國生命集團(08296.HK):年度淨虧收窄58%至350.8萬元
格隆匯3月31日丨中國生命集團(08296.HK)公佈未經審核全年業績,截至二零一九年十二月三十一日止年度,公司實現收益6661萬元(人民幣,下同),同比增長6.3%;毛利3204.2萬元,同比增長14.89%;公司擁有人應占虧損350.8萬元,同比收窄58%;每股虧損0.47分,不派息。
公告顯示,截至2019年12月31日止年度,受惠於中國消費上升及人口持續老齡化,集團於中國大陸的業務較2018同期錄得增長。同時,其于越南市場亦錄得殯儀業務增長。最近於台灣設立的護老服務業務停滯。
另一方面,集團已成功於中國推進年初所簽訂之幹細胞及免疫細胞銷售代理協議內的項目,及於中國香港新開展高級生物科技設備銷售業務。
.
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.